[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Myeloid neoplasms](https://durgical.com/en/haematology/areas/myeloid/) › Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)

# Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)

- Treatment and support

New treatments turn the immune system against blood cancers. They can work when chemotherapy fails, but they can set off a dangerous fever storm.

Updated Nov 15, 2026

## Key points

- Antibody = label; bispecific = handcuffs linking T cell and tumour; CAR-T = rebuilt T cell that multiplies.
- CRS: fever first, then low [blood pressure](https://durgical.com/en/physiology/systolic-diastolic-mean-and-pulse-pressure/) and hypoxia; [tocilizumab](https://durgical.com/en/pharmacology/tocilizumab/), steroids if severe.
- ICANS: confusion, aphasia, handwriting change, seizures; steroids.
- [Daratumumab](https://durgical.com/en/pharmacology/daratumumab/) interferes with the antibody screen: tell the blood bank.
- Anti-CD20: screen for hepatitis B first.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Three ways to point the immune system at a blood cancer
- Common traps
- Elsewhere in DurgiPedia

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

Three families use the immune system against blood cancers. Monoclonal [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) bind a surface marker (CD20 on B cells, CD38 on plasma cells, CD30, CD33, CD22) and kill by recruiting immune cells and complement or by delivering an attached toxin ([antibody-drug conjugates](https://durgical.com/en/pharmacology/classes/antibody-drug-conjugates/)). [Bispecific T-cell engagers](https://durgical.com/en/pharmacology/classes/bispecific-t-cell-engagers/) bind CD3 on a T cell and a tumour marker (CD19, BCMA, CD20) at once, linking the two. [CAR-T cells](https://durgical.com/en/biochemistry/topics/gene-therapy/) are the patient's own T cells, engineered to carry a chimeric antigen receptor against CD19 or BCMA, that multiply in the body. The more T cells are activated, the greater the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

## How to think about it

Think labels, handcuffs and rebuilt police. An antibody is an address label stuck on the cancer cell, calling the body's killers or carrying a poison. A bispecific is a pair of handcuffs chaining any passing T cell to the cancer cell. A CAR-T cell is a police officer rebuilt with a new receiver who lives and multiplies. The more police are activated at once, the bigger the cytokine fire: CRS and ICANS are the price of activation.

## What to know

- Anti-CD20 ([rituximab](https://durgical.com/en/pharmacology/rituximab/), [obinutuzumab](https://durgical.com/en/pharmacology/obinutuzumab/)): B-cell lymphomas and CLL; infusion reactions, hepatitis B reactivation, low antibodies and infections.
- Anti-CD38 (daratumumab): myeloma; it binds the test red cells used in the antibody screen and makes them all look positive, so the blood bank must know before starting.
- Antibody-drug conjugates: [brentuximab vedotin](https://durgical.com/en/pharmacology/brentuximab-vedotin/) (CD30; nerve damage), gemtuzumab and [inotuzumab ozogamicin](https://durgical.com/en/pharmacology/inotuzumab-ozogamicin/) (CD33 and CD22; [liver](https://durgical.com/en/anatomy/liver/) sinusoidal obstruction).
- Bispecifics: [blinatumomab](https://durgical.com/en/pharmacology/blinatumomab/) (CD19 × CD3) for B-cell ALL, [teclistamab](https://durgical.com/en/pharmacology/teclistamab/) (BCMA × CD3) for myeloma; CRS and neurotoxicity mostly with the first doses.
- CAR-T: CD19 for B-cell lymphomas and B-cell ALL ([tisagenlecleucel](https://durgical.com/en/pharmacology/tisagenlecleucel/), [axicabtagene ciloleucel](https://durgical.com/en/pharmacology/axicabtagene-ciloleucel/)); BCMA for myeloma.
- CRS starts with fever, then low blood pressure and low [oxygen](https://durgical.com/en/pharmacology/oxygen/), usually within days; ICANS causes confusion, word-finding difficulty, changes in handwriting, tremor, seizures and brain swelling, often during or after CRS.

## How it is done (and why)

- CAR-T: collect the patient's T cells by apheresis; bridging treatment controls the cancer while the cells are made.
- The T cells are engineered in a laboratory to express the chimeric receptor and grown in large numbers.
- Lymphodepleting chemotherapy ([fludarabine](https://durgical.com/en/pharmacology/fludarabine/) and [cyclophosphamide](https://durgical.com/en/pharmacology/cyclophosphamide/)) clears space so the CAR-T cells can expand.
- Infuse the cells and watch for fever, blood pressure, oxygen and neurological signs several times a day, with a simple writing and naming test.
- CRS: grade by fever, hypotension and hypoxia; give tocilizumab (anti-IL-6 receptor) and add steroids if severe, with supportive and ICU care.
- ICANS: steroids are the main treatment; seizure prevention and ICU care if severe; tocilizumab alone does not treat it.
- Afterwards: the patient stays near the treating centre for weeks, does not drive for a period, and is followed for low counts, infections and low antibodies.

## Three ways to point the immune system at a blood cancer

| Feature | Monoclonal antibody | Bispecific T-cell engager | CAR-T cells |
| --- | --- | --- | --- |
| What it is | An antibody (sometimes carrying a toxin) against a tumour marker | A molecule binding CD3 on T cells and a tumour marker | The patient's T cells engineered with a new receptor |
| Who does the killing | Natural killer cells, macrophages, complement, or the toxin | The patient's own T cells, linked to the tumour | The engineered T cells, which multiply in the body |
| How it is given | Repeated infusions or injections | Repeated infusions or injections, stepped up at first | One infusion after lymphodepletion |
| Main early danger | Infusion reaction | CRS and neurotoxicity, mostly at the start | CRS and ICANS, often severe |
| Long-term effect | B-cell depletion with anti-CD20 | Low antibodies and infections | Long B-cell aplasia, low antibodies, prolonged low counts |

## Risks and precautions

- Fever after CAR-T or a bispecific may be CRS, but the patient is often neutropenic: take cultures and start antibiotics while treating CRS.
- ICANS is found early by asking the patient to name objects, write a sentence and count backwards: a decline in handwriting or speech is an early sign.
- Screen for hepatitis B before anti-CD20 antibodies: reactivation can cause liver failure.
- Tell the blood bank before daratumumab and give a baseline group and screen: the interference can delay compatible blood.
- After CD19-directed therapy the B cells are gone for a long time: antibody levels fall and immunoglobulin replacement and infection prophylaxis may be needed.

## Monitoring and next step

- Before treatment: count, kidney and liver tests, hepatitis B, hepatitis C and HIV, group and screen (before anti-CD38), and an immunoglobulin level.
- After CAR-T or bispecific: daily count, CRP and ferritin, kidney and liver tests, and coagulation; very high ferritin with falling counts suggests an HLH-like syndrome.
- Fever: blood cultures and a search for infection every time, even when CRS seems obvious.
- Neurological change: neurological exam and grading score, brain imaging and EEG if severe or seizures are suspected.
- Months later: immunoglobulin levels, count recovery and response assessment.

## Common traps

- **Treating fever after CAR-T as CRS alone**: it may be neutropenic sepsis.
- **Relying on tocilizumab for ICANS**: it does not cross into the brain well; steroids are the treatment.
- **Forgetting to warn the blood bank before daratumumab**: the antibody screen is then unexplained and blood is delayed.
- **Starting rituximab without hepatitis B screening**: the screening comes first.
- **Dismissing a small change in handwriting or speech after CAR-T**: it can be the first sign of ICANS.

## Test yourself

Think of the answer, then tap the question to see it.

## Two days after CAR-T infusion a patient has a high fever, then low blood pressure. What is the likely syndrome, and what else must be excluded?

Cytokine release syndrome; infection must be excluded at the same time with cultures and antibiotics, since the patient is often neutropenic.

## Why is tocilizumab not enough for a patient with ICANS but no CRS?

It blocks the IL-6 receptor in the blood but does not reach the brain well; steroids are the main treatment for ICANS.

## Why does a myeloma patient on daratumumab have a positive antibody screen against every test cell?

Daratumumab binds CD38, which is also on the reagent red cells, so all test cells react; the blood bank uses special methods to find compatible blood.

## What is the main difference between a bispecific T-cell engager and a CAR-T cell?

A bispecific is a drug that links the patient's existing T cells to the tumour and must be given repeatedly; CAR-T cells are engineered T cells given once that multiply.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/antibodies-bispecifics-and-car-t-cells-how-they-work-and-their-emergencies/)

## Elsewhere in DurgiPedia

- [Cancer immunotherapy: checkpoint inhibitors, CAR-T and vaccines](https://durgical.com/en/immunology/cancer-immunotherapy-checkpoint-inhibitors-car-t-and-vaccines/)
- [Monoclonal antibodies and biologics: naming and targets](https://durgical.com/en/immunology/monoclonal-antibodies-and-biologics-naming-and-targets/)
- [Cytokine storm: CRS, HLH, sepsis and severe COVID-19](https://durgical.com/en/immunology/cytokine-storm-crs-hlh-sepsis-and-severe-covid-19/)
- [How monoclonal antibodies are made: hybridomas to fully human](https://durgical.com/en/immunology/how-monoclonal-antibodies-are-made-hybridomas-to-fully-human/)
- [Treating antibody diseases: IVIG, plasma exchange, B-cell depletion](https://durgical.com/en/immunology/treating-antibody-diseases-ivig-plasma-exchange-b-cell-depletion/)

## Connections

## Related 8

- [Stem cell transplantation: autologous or allogeneic, and what can go wrong](https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/)
- [Group, screen and crossmatch: who can receive what](https://durgical.com/en/haematology/group-screen-and-crossmatch-who-can-receive-what/)
- [Hodgkin versus non-Hodgkin lymphoma](https://durgical.com/en/haematology/hodgkin-versus-non-hodgkin-lymphoma/)
- [A paraprotein: MGUS, smouldering myeloma, myeloma or Waldenström?](https://durgical.com/en/haematology/a-paraprotein-mgus-smouldering-myeloma-myeloma-or-waldenstrom/)
- [Acute leukaemias: AML, ALL and the emergency called APL](https://durgical.com/en/haematology/acute-leukaemias-aml-all-and-the-emergency-called-apl/)
- [Tumour lysis syndrome: prevent, recognise, treat](https://durgical.com/en/haematology/tumour-lysis-syndrome-prevent-recognise-treat/)
- [Myeloma care: bones, kidneys, infections and treatment principles](https://durgical.com/en/haematology/myeloma-care-bones-kidneys-infections-and-treatment-principles/)
- [Staging and treating lymphoma: PET-CT, the Lugano stages and treatment principles](https://durgical.com/en/haematology/staging-and-treating-lymphoma-pet-ct-the-lugano-stages-and-treatment-principles/)

## Related conditions 5

- [Non-Hodgkin lymphoma](https://durgical.com/en/conditions/non-hodgkin-lymphoma/)
- [Acute leukaemia (AML and ALL)](https://durgical.com/en/conditions/acute-leukaemia/)
- [Multiple myeloma](https://durgical.com/en/conditions/multiple-myeloma/)
- [Chronic lymphocytic leukaemia](https://durgical.com/en/conditions/chronic-lymphocytic-leukaemia/)
- [Hodgkin lymphoma](https://durgical.com/en/conditions/hodgkin-lymphoma/)

## In Pharmacology 12

- [Rituximab](https://durgical.com/en/pharmacology/rituximab/)
- [Obinutuzumab](https://durgical.com/en/pharmacology/obinutuzumab/)
- [Daratumumab](https://durgical.com/en/pharmacology/daratumumab/)
- [Brentuximab vedotin](https://durgical.com/en/pharmacology/brentuximab-vedotin/)
- [Gemtuzumab ozogamicin](https://durgical.com/en/pharmacology/gemtuzumab-ozogamicin/)
- [Inotuzumab ozogamicin](https://durgical.com/en/pharmacology/inotuzumab-ozogamicin/)
- [Blinatumomab](https://durgical.com/en/pharmacology/blinatumomab/)
- [Teclistamab](https://durgical.com/en/pharmacology/teclistamab/)
- [Tisagenlecleucel](https://durgical.com/en/pharmacology/tisagenlecleucel/)
- [Axicabtagene ciloleucel](https://durgical.com/en/pharmacology/axicabtagene-ciloleucel/)
- [Tocilizumab](https://durgical.com/en/pharmacology/tocilizumab/)
- [Dexamethasone](https://durgical.com/en/pharmacology/dexamethasone/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells) (National Cancer Institute (NIH), 2024); [Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies) (National Cancer Institute (NCI), 2026); [Blinatumomab Injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a614061.html) (MedlinePlus (U.S. National Library of Medicine), 2024); [Teclistamab-cqyv Injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a622076.html) (MedlinePlus (U.S. National Library of Medicine), 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/antibodies-bispecifics-and-car-t-cells-how-they-work-and-their-emergencies/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/antibodies-bispecifics-and-car-t-cells-how-they-work-and-their-emergencies/
